Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma
Hematology, Oncology and Stem Cell Therapy. 2011; 4 (1): 1-9
in English
| IMEMR
| ID: emr-110141
ABSTRACT
High-dose chemotherapy followed by autologous hematopoietic cell transplantation continues to play an integral role in the treatment strategy in patients with newly diagnosed multiple myeloma. Incorporation of newer potent anti-myeloma agents has further improved outcomes. However, disease relapse or proggression remains a challenge after autologous transplantation. Allogeneic hematopoietic cell transplantattion remains the only potentially curative modality for some patients due in part to graft-versus-myeloma effect. High transplant-related mortality, in the range of 30% to 40%, previously seen with myeloablative conditioning regimens including total body irradiation plus cyclophosphamide has been significantly reduced by introducing less ablative preparative regimens, so called reduced-intensity conditioning. Cumulative evidence suggests encouraging prospects for allogeneic transplantation through improved outcomes of myeloma patients [overall survival exceeding 70% at 2 years in some studies]; however, which patient population would benefit most from this treatment remains to be defined. Newer strategies to augment graft-versus-myeloma effect and minimize post transplant toxicities are in need of further improvement in patients with myeloma
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Recurrence
/
Transplantation, Homologous
/
Disease-Free Survival
/
Transplantation Conditioning
/
Multiple Myeloma
Limits:
Humans
Language:
English
Journal:
Hematol. Oncol. Stem Cell Ther.
Year:
2011
Similar
MEDLINE
...
LILACS
LIS